AccueilATHA • NASDAQ
add
Athira Pharma
0,64 $
Après la clôture :(0,47 %)-0,0030
0,64 $
Fermé : 22 nov., 19:49:03 UTC−5 · USD · NASDAQ · Clause de non-responsabilité
Dernière clôture
0,66 $
Variation sur la journée
0,63 $ - 0,66 $
Plage sur l'année
0,41 $ - 4,30 $
Capitalisation boursière
24,64 M USD
Volume moyen
9,62 M
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités des marchés
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | — | — |
Charges d'exploitation | 25,49 M | -27,25 % |
Résultat net | -28,74 M | 12,83 % |
Marge bénéficiaire nette | — | — |
Bénéfice par action | — | — |
EBITDA | -25,25 M | 27,44 % |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 68,86 M | -60,19 % |
Total des actifs | 86,25 M | -53,30 % |
Total du passif | 28,66 M | -4,25 % |
Total des capitaux propres | 57,58 M | — |
Actions en circulation | 38,67 M | — |
Ratio cours/valeur comptable | 0,44 | — |
Rentabilité des actifs | -64,54 % | — |
Retour sur capitaux | -88,74 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -28,74 M | 12,83 % |
Trésorerie (opérations) | -23,02 M | 4,01 % |
Trésorerie (invest.) | 18,04 M | -12,81 % |
Trésorerie (financement) | 12,00 k | — |
Variation nette en trésorerie | -4,97 M | -50,94 % |
Flux de trésorerie dispo. | -10,13 M | 13,86 % |
À propos
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Date de fondation
2011
Siège social
Site Web
Employés
66
